ArticleFrontiers in neurology2026
Excessive supraventricular ectopic activity and new-onset ischemic stroke: a retrospective cohort study with prospective outcome ascertainment.
Article in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Excessive supraventricular ectopic activity (ESVEA), a marker of both paroxysmal atrial fibrillation (pAF) and underlying atrial cardiomyopathy, may serve as an earlier electrographic predictor of cryptogenic ischemic stroke than pAF itself. This study aimed to investigate the association between ESVEA and the risks of new-onset ischemic stroke and all-cause mortality in an Asian population, and to explore a potential data-driven threshold that requires external validation. Methods: In this retrospective cohort study with prospective outcome ascertainment, data were collected from 446 patients without a history of atrial fibrillation or stroke across three hospitals in China. Based on the results of 24-h ambulatory ECG monitoring, patients in the top 15% of the cohort (premature atrial complex [PAC] rate ≥100 beats/24 h or paroxysmal atrial tachycardia [PAT] episode count ≥22 episodes/24 h) were defined as the ESVEA group; the remainder comprised the non-ESVEA group. The incidence of new-onset ischemic stroke and all-cause mortality was compared between groups during follow-up, after adjustment for confounding factors such as age and hypertension. Results: The median follow-up duration was 13 months. In a multivariable Cox proportional hazards model with a time-varying coefficient for age, using new-onset ischemic stroke and all-cause mortality as endpoints, after adjusting for other risk factors, ESVEA was significantly associated with new-onset ischemic stroke (HR:2.798; 95% CI:1.064 to 7.359; Conclusion: In this retrospective cohort study with prospective outcome ascertainment, ESVEA was associated with an increased risk of new-onset ischemic stroke and all-cause mortality in Asian subjects without prior stroke or AF. These exploratory findings suggest that ESVEA may be a useful risk marker, but require validation in larger prospective studies before clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.